Nobels F R, de Herder W W, Kwekkeboom D J, Coopmans W, Mulder A, Bouillon R, Lamberts S W
Department of Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Eur J Endocrinol. 1994 Dec;131(6):589-93. doi: 10.1530/eje.0.1310589.
We evaluated whether measuring serum levels of chromogranin A, a marker of neuroendocrine tumours, could be useful in the differential diagnosis between pituitary, adrenal and ectopic causes of Cushing's syndrome. Thirty patients with Cushing's syndrome were studied. The localization of the tumours responsible was pituitary in 15, adrenal in 5 and ectopic in 10 patients. Serum concentrations of chromogranin A were measured in all patients. Petrosal sinus sampling for chromogranin A was performed in the cases with pituitary-dependent Cushing's syndrome. Immunohistochemical staining for chromogranin A was carried out on part of the tumour specimens. Slightly elevated serum levels of chromogranin A (range 223-262 micrograms/l) were detected in inferior petrosal sinus and peripheral venous samples from three patients with pituitary-dependent Cushing's syndrome. Serum chromogranin A showed no significant pituitary to peripheral gradient in these patients. Chromogranin A levels were not elevated in cases of adrenal Cushing's syndrome. Markedly elevated concentrations (range 270-13,900 micrograms/l) were shown in seven of 10 patients with neuroendocrine tumours with ectopic adrenocorticotrophin (ACTH) and/or corticotrophin-releasing hormone (CRH) production. Widespread metastasis was present in all these cases. Subjects with "occult" carcinoid tumours, with limited spread, had normal chromogranin A levels. Immunohistochemical staining for chromogranin A was positive in three out of five pituitary adenomas and in all neuroendocrine tumours with ectopic ACTH and/or CRH production, while it was negative in all adrenocortical tumour specimens. It is concluded that elevated serum levels of chromogranin A can serve as markers of neuroendocrine tumours with ectopic ACTH and/or CRH production.(ABSTRACT TRUNCATED AT 250 WORDS)
我们评估了检测嗜铬粒蛋白A(一种神经内分泌肿瘤标志物)的血清水平是否有助于鉴别库欣综合征的垂体、肾上腺及异位病因。研究了30例库欣综合征患者。其中15例患者的致病肿瘤位于垂体,5例位于肾上腺,10例为异位肿瘤。检测了所有患者的血清嗜铬粒蛋白A浓度。对垂体依赖性库欣综合征患者进行了岩下窦嗜铬粒蛋白A采样。对部分肿瘤标本进行了嗜铬粒蛋白A免疫组化染色。在3例垂体依赖性库欣综合征患者的岩下窦和外周静脉样本中检测到血清嗜铬粒蛋白A水平轻度升高(范围为223 - 262微克/升)。这些患者的血清嗜铬粒蛋白A在垂体与外周之间无明显梯度变化。肾上腺性库欣综合征患者的嗜铬粒蛋白A水平未升高。10例产生异位促肾上腺皮质激素(ACTH)和/或促肾上腺皮质激素释放激素(CRH)的神经内分泌肿瘤患者中有7例其嗜铬粒蛋白A浓度显著升高(范围为270 - 13900微克/升)。所有这些病例均有广泛转移。“隐匿性”类癌肿瘤且转移局限的患者,其嗜铬粒蛋白A水平正常。5例垂体腺瘤中有3例嗜铬粒蛋白A免疫组化染色呈阳性,所有产生异位ACTH和/或CRH的神经内分泌肿瘤均呈阳性,而所有肾上腺皮质肿瘤标本均为阴性。结论是血清嗜铬粒蛋白A水平升高可作为产生异位ACTH和/或CRH的神经内分泌肿瘤的标志物。(摘要截短至250字)